Acyclic nucleoside phosphonate antivirals activate gene expression of monocyte chemotactic protein 1 and 3

Journal of Biomedical Science

Volumn 14, Issue 1, 2007, Pages 59-66

  Potměšil, Petr ^a   Holý, Antonín ^b   Kmoníčková, Eva ^a,c   Křížková, Jana ^a   Zídek, Zdeněk ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acyclic nucleoside phosphonate; HIV; Monocyte chemotactic protein; Nuclear factor B

Indexed keywords

2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; ACYCLIC NUCLEOSIDE; ADENINE; ANTIVIRUS AGENT; BASE; CYANOACRYLATE DERIVATIVE; CYCLOPROPANE DERIVATIVE; HETEROCYCLIC COMPOUND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; N 6 CYCLOHEXYLMETYL 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; N 6 CYCLOOCTYL 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; N 6 CYCLOPENTYL 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; N 6 CYCLOPENTYL 9 [2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; N 6 CYCLOPROPYL 9 [2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; N 6 DIMETHYLAMINOETHYL 9 [2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; N 6 ISOBUTYL 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-HIV AGENTS; CARBOXYPEPTIDASES A; CELLS, CULTURED; CHEMOKINE CCL2; FEMALE; HIV; HIV INFECTIONS; HUMANS; MACROPHAGES, PERITONEAL; MICE; NUCLEOSIDES; VIRUS REPLICATION;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33847169017     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9116-4     Document Type: Article

References (35)

1. De Clercq E., HIV-chemotherapy and prophylaxis: new drugs, leads and approaches. Int. J. Biochem. Cell Biol. 36:1800-1822, 2004.
2. Kramata P., Votruba I., Otová B. and Holý A., Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases a, d and e. Mol. Pharmacol. 49: 1005-1011, 1996.
3. Crowe S, New reverse transcriptase inhibitors. Adv. Exp. Med. Biol. 458: 183-197, 1999.
4. Holý A., Votruba I., Merta A., Černý J., Veselý J., Vlach J. and Sediva K., Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res. 13: 295-311, 1990.
5. 6-substituted adenines, and 2,6-diaminopurines. Eur. J. Pharmacol. 475: 149-159, 2003.
6. Zídek Z., Franková D. and Holý A., Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein-1 alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1 b) production. Antimicrob. Agents Chemother. 45: 3381-3386, 2001.
7. Loetscher P., Seitz M., Clark-Lewis I., Baggiolini M. and Moser B., Monocyte chemoattractant proteins MCP-1, MCP-2 and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB 8: 1055-1060, 1994.
8. Van Coillie E., Van Damme J. and Opdenakker G., The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 10: 61-86, 1999.
9. Bacon K., Baggiolini M., Broxmeyer H., Horuk R., Lindley I., Mantovani A., Maysushima K., Murphy P., Nomiyama H. and Oppenheim J., Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 22: 1067-8, 2002.
10. 6-substituted adenines, 2,6-diaminopurines and related compounds. Collect. Czechoslovak. Chem. Commun. 66: 1545-1592, 2001.
11. Chen Z., Yu S., Bakhiet M., Winblad B. and Zhu J., The chemokine receptor CCR5 is not necessary inflammatory mediator in kainic acid induced hippocampal injury: evidence for a compensatory effect by increased CCR2 and CCR3. J. Neurochem. 86: 61-68, 2003.
12. Hu J., Li G., Wang W., Zhu J., Li Y., Zhou G. and Sun Q., Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. World J. Gastroenterol. 8: 1067-1072, 2002.
13. Park M., Hoffmann K., Cheever A., Amichay D., Wynn T. and Farber J., Patterns of chemokine expression in models of Schistosoma mansoni inflammation and infection reveal relationships between type 1 and type 2 responses and chemokines in vivo. Infect. Immun. 69: 6755-6768, 2001.
14. Schreck R., Meier B., Mannel D., Droge W. and Baeuerle P., Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175: 1181-1194, 1992.
15. Frade J., Llorente M., Mellado M., Alcami J., Gutierrez-Ramos J., Zaballos A., Real G. and Martinez C., The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. J. Clin. Invest. 100:497-502, 1997.
16. Blanpain C., Migeotte I., Lee B., Vakili J., Doranz B., Govaerts C., Vassart G., Doms R. and Parmentier M., CCR5 binds multiple CC-chemokines: MCP-3 acts as natural antagonist. Blood 94: 1899-1905, 1999.
17. Vicenzi E., Alfano M., Ghezzi S., Gatti A., Veglia F., Lazzarin A., Sozzani S., Mantovani A. and Poli G., Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1a and MCP-3, and enhancement by MCP-1. J. Leukoc. Biol. 68: 405-412, 2000.
18. Gonzalez E., Rovin B., Sen L., Cooke G., Dhanda R., Mummidi S. and Kulkarni H., HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Natl. Acad. Sci. USA 99: 13795-13800, 2002.
19. Eugenin E., D'Aversa T., Lopez L., Calderon T. and Berman J., MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 85: 1299-1311, 2003.
20. Hokeness K., Kuziel W., Biron C. and Salazar-Mather T., Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory response and antiviral defense in liver. J. Immunol. 174: 1549-1556, 2005.
21. Hirose K., Hakozaki M., Nyunoya Y., Kobayashi Y., Matsushita K., Takenouchi T. and Mikata A., Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72: 708-714, 1995.
22. Rollins B. and Sunday M., Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell Biol. 11: 3125-3131, 1991.
23. Mantovani A., Bottazzi B., Sozzani S., Peri G., Allavena P., Dong Q., Vecchi A. and Colota F., Cytokine regulation of tumour-associated macrophages. Res. Immunol. 144: 280-283, 1993.
24. Sarafi M., Garcia-Zepeda E., MacLean J., Charo I. and Luster A., Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is structural and functional homologue of human MCP-1. J. Exp. Med. 185: 99-109, 1997.
25. Gong W., Howard O., Turpin J., Grimm M., Ueda H., Gray P., Raport C., Oppenheim J. and Wang J., Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry replication. J. Biol. Chem. 273: 4289-4292, 1998.
26. Berger E., Murphy P. and Farber J., Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease. Annu. Rev. Immunol. 17: 657-700, 1999.
27. Schols D., Proost P., Damme J. and De Clercq E., RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE). J. Virol. 74: 7300-7304, 1997.
28. Modi W., Goedert J., Strathdee S., Buchbinder S., Detels R., Donfield S., O'Brien S. and Winkler C., MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 17: 2357-2365, 2003.
29. Chada S., Ramesh R. and Mhashilkar A., Cytokine- and chemokine-based gene therapy for cancer. Curr. Opin. Mol. Ther. 5: 463-474, 2003.
30. Wetzel K., Menten P., Opdenakker G., Van Damme J., Grone H., Giese N., Vecchi A., Sozzani S., Cornelis J., Rommelaere J. and Dinsart C., Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J. Gene Med. 3: 326-337, 2001.
31. Fioretti F., Fradelizi D., Stoppacciaro A., Ramponi S., Ruco L., Minty A., Sozzani S., Garlanda C., Vecchi A. and Mantovani A., Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol. 161: 342-346, 1998.
32. Pahl H.L., Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
33. Li X., Massa P.E., Hanidu A., Peet G.W., Aro P., Savitt A., Mische S., Li J. and Marcu K.B., IKKalpha , IKKbeta and NEMO/IKKgamma are each required for the NFkappa B mediated inflammatory response program. J. Biol. Chem. 277: 45129-45140, 2002.
34. Potmesil P., Krecmerova M., Kmonickova E., Holy A. and Zidek Z., Nucleotide analogues with immunobiological properties: 9-[2-Hydroxy-3- (phosphonomethoxy)propyl]-adenine (HPMPA), -2,6-diaminopurine (HPMPDAP), and their N(6)-substituted derivatives. Eur. J. Pharmacol. 540: 191-199, 2006.
35. Wuyts W., Vanaudenaerde B., Dupont L., Demedts M. and Verleden G., Involvement of p38 MAPK, p42/p44 and NF kappa B in IL-1beta induced chemokine release in human airway smooth muscle cells. Respir. Med. 97: 811-817, 2003.